Background: Benign disorder of breast in female usually seen in reproductive period of life, is thought to be largely hormone induced and there is a dramatic fall in the incidence after menopause due to cessation of ovarian stimulation.
Introduction
Breast is a dynamic structure which undergoes changes throughout women's reproductive life, and superimposed on this cyclical changes throughout menstrual cycle. Both benign and malignant lesion is very frequent to affect breast with various morphology. Non cancerous disease of the breast have assumed increasing importance because of the public awareness of the breast cancer. 1 Globally benign pathological states accounts for approximately 90% of the clinical presentation related to the breast. 2 It is therefore important for surgeons, pathologists and oncologists to recognize benign lesions, both to distinguish them from in situ and invasive breast cancer and to assess a patient's risk of developing breast cancer, so that the most appropriate treatment modality for each case can be established. 3 The cyclical changes due to variations in estrogen and progesterone result in increased mitosis around days 22-24 of the menstrual cycle but apoptosis restores the balance across the cycle. 4 Incidence of benign lesions is common in the second decade reaching on its peak at fourth and fifth decade of life 3 
Statistical method:
Obtained data was analyzed digitally with SPSS 20 (Social Package Statistical Service). Quantitative data was expressed as Mean ± SD.
Results

Table I
Showing outcome of the study 
Table V
Serum estradiol level among study subjects.
Serum Estradiol (pg/ml) (26.6-161 pg/ml) Range 9.52-397 pg/ml. Mean± SD 71.16± 57.63 pg/ml.
Table VI
Serum testosterone level among study subjects. In this study, clinicopathological type of benign breast disease, level of hormones affect normal breast development and their probable link with benign breast disease were observed. In our study age range of the patients were 13 years to 58 years with the mean age 28 ± 8.46 years. A sub Saharan African tertiary institute study by Okoth C et al. 2013 showed that their mean age for benign breast disease was 28.4 years6 which is very similar to my study. Probably the same or almost same socio economic condition of the two region of the world brings the almost same result. Moreover this study has similarity with a study held in Pakistan on 2013. 7 If we consider the mean age of the patients with fibroadenoma; it was 23.61. This is very similar with the other study regarding benign breast disease conducted by Katiyar S & Nigam S 2013. 8 In this study contraceptive history of each and every patients were noted meticulously. Patients using barrier or other nonhormonal methods were labeled as patients not using contraceptives. On the other hand patients having oral contraceptive pill, emergency contraceptive pill, Intra muscular hormonal injections and with subdermal implant were labeled as patients using contraceptive. 64 patients among 150 patients, that is 42.7 % uses hormonal product as contraception and 86 (57.3%) women does not use hormonal contraceptive.
In 2015 unicef published a data where they showed that in south east Asia rate of contraception use is 57-64% . As Bangladesh possesses a male predominant social and familial structure rate of use contraception among male is low unlike other developed countries. In this study we found that 42.7% woman uses hormonal contraceptive product matches with the data providedby united nation as approximately 15-20% of our male population uses contraceptive method. In our study youngest patient of fibroadenoma was 14 years old and the eldest patient was 58 years old. Mean age of fibroadenoma patients were 23.61 years and most of the fibroadenoma patients were within the age limit of 20-30 years. This result is near similar with the result of Jayaprashad N held in india. 9 Serum oestrogen has several normal values accoding to phase of menstruation. For this reason several author collected blood sample during follicular phase of menstrual cycle , presumably following the common sense notion that it is best to sample the hormones when its level is high. 10 For this reason we collected all blood sample from 3rd to 7th day of follicular phase of menstrual cycle. Range of serum oestrogen level among study populations were 9.52 pg/ml-397 pg/ml. Mean±SD was 71.16± 57.63 pg/ml. In study of 588 patients conducted in Greece showed that median 10th to 90th percentile of measured oestrogen was 104 pg/ml in benign breast disease patient. 11 Where as in our study it was 100 pg/ml which is very similar to the study of E Samoli et al. 2013. In case of fibroadenoma of breast range of serum oestrogen was 14.66-313 pg/ml with the mean ± SD was 76.94±57.69 pg/ml. And in case of fibrocystic disease range of serum oestrogen level was 9.52 to 397 pg/ml and mean ± SD was 68.20 ± 57.47 pg/ml. Among 38 patients of fibroadenoma 3 (7.89%) patients had oestrogen level more than normal and 3 (7.89%) patients had oestrogen level lower than normal. This data does not reflect any definitive relation between abnormal oestrogen level with fibroadenoma. In case of fibrocystic disease 10 patients (10.42%) out 96 patients had oestrogen level lower than normal value and 2 patients (2.08%) had oestrogen level more than normal value. There might have some connections between low oestrogen level with fibrocystic disease but this is not possible to comment regarding this connection by this small sample study. It demands more concentration and a large sample study to comment about the connection.
In this study there were 6 patients who were diagnosed as duct ectasia and periductal mastitis. These 6 patients presented with characteristics nipple discharge. Range of oestrogen value among this 6 patients were 23.46 to 193.87 pg/ml. Mean ± SD was 78.56 ± 67.19 pg/ml. 1 patient had oestrogen level below normal value and 1 patient had oestrogen value above normal which denies any hormonal connection.
Five patients in this study had fibroadenoma in one breast and fibrocystic disease in opposite breast. Regarding this patient Mean ± SD of serum oestrogen level was 94.92 ± 72.92 with range of 17.92 -201.19 pg/ml. 1 patient had oestrogen level below normal and 1 patient had oestrogen level above normal. Mean oestrogen level for fibroadenoma with fibrocystic disease is higher than the mean oestrogen level for single fibroadenoma or fibrocystic disease.In this study women who fulfilled inclusion and exclusion criteria; serum testosterone level were measured. Blood sample were drawn in days 3-7 day of the follicular phase of the menstrual cycle and after an 8-hour fast. Range of serum testosterone level among study populations were .03 to 2.12 nmol/L. Mean ± SD was 0.59 ± 0.42 nmol/L.
Range of Serum prolactin level among the study subjects were 3.09 to 98.43 ng/ml with mean ± SD was 22.61 ± 16.65 ng/ml. Among the study populations 22 patients had prolactin level higher than normal which is 14.67%. Aisha M et al. 2007 showed in their study that 30% of their study subjects had higher prolactin level in benign breast disease 12 in case of Pakistani women.Probably the geographic variation among study subjects brings this diversity in our result.
The rationality of the study is to reveal the hormonal connection with benign breast disease which can prevent undue surgical treatment as well as blind hormonal treartment for benign breast disease.Though in some patients hormone level has some alterations from normal value but this study is not conclusive to establish the relationship between benign breast disease and oestrogen, testosterone and prolactin. Further study with large sample size might establish relation between these three hormone and benign breast disease.
